Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 7/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19512327 | 0.87 | NPC1 (0.44) | MAPTTP53LMNACSNK2BCSNK2A2 | |
| SCHEMBL2030256 | 0.86 | CSNK2B (0.42) | ABCB1ABCG2MAPTTP53LMNA | |
| SCHEMBL2030258 | 0.86 | CSNK2B (0.42) | ABCB1ABCG2MAPTTP53LMNA | |
| SCHEMBL19526882 | 0.84 | CSNK2B (0.37) | ABCB1ABCG2MAPTTP53LMNA | |
| SCHEMBL2031560 | 0.81 | ABCB1 (0.43) | ABCB1ABCG2MAPTTP53LMNA | |
| SCHEMBL2030673 | 0.81 | CSNK2B (0.47) | MAPTTP53CSNK2BCSNK2A2CSNK2A1 | |
| SCHEMBL12645621 | 0.77 | BUB1 (0.36) | ABCB1ABCG2MAPTTP53LMNA | |
| SCHEMBL19526843 | 0.77 | CSNK2B (0.41) | ABCB1ABCG2MAPTLMNACSNK2B | |
| SCHEMBL1934230 | 0.76 | CSNK2B (0.63) | CSNK2BCSNK2A2CSNK2A1 | |
| SCHEMBL2029816 | 0.76 | EPHX2 (0.39) | MAPTCSNK2BRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B9 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-11-01 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| EP-2509602-B1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | SENHWA BIOSCIENCES INC (TW) | 2017-01-25 | — | — | EP | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| US-8575177-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2013-11-05 | — | — | US | disclosed |
| EP-2509602-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068667-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152240-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CDK2, CKS2, CSNK2A1 | ABCB1 3043/4885ABCG2 2971/4885MAPT 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.